Fig. 3From: A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success ratesrNPV calculations for the four interventions using indication specific FEC high and low costs and phase specific cumulative progressive success rate. Progressive success rates indicated in Table 5 were used in the rNPV calculations for indication specific low (red line) and indication specific high (blue line) value calculations. a Chemical entity—heart. b Biological—heart. c Chemical entity—diabetes. d Biological—diabetesBack to article page